Cigna Investments Inc. New Sells 81 Shares of Agilent Technologies, Inc. (NYSE:A)

Cigna Investments Inc. New lowered its position in Agilent Technologies, Inc. (NYSE:A) by 2.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,016 shares of the medical research company’s stock after selling 81 shares during the period. Cigna Investments Inc. New’s holdings in Agilent Technologies were worth $447,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Crewe Advisors LLC increased its holdings in Agilent Technologies by 114.8% during the second quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after buying an additional 101 shares during the last quarter. Livelsberger Financial Advisory purchased a new stake in shares of Agilent Technologies in the 3rd quarter worth $28,000. Ridgewood Investments LLC bought a new position in Agilent Technologies in the 2nd quarter worth $29,000. Fortitude Family Office LLC lifted its position in Agilent Technologies by 68.3% during the third quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 95 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC bought a new stake in Agilent Technologies during the second quarter valued at about $39,000.

Agilent Technologies Stock Up 5.0 %

NYSE A opened at $136.87 on Friday. The stock has a 50 day moving average price of $139.73 and a 200-day moving average price of $138.05. Agilent Technologies, Inc. has a one year low of $102.70 and a one year high of $155.35. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78. The company has a market capitalization of $39.33 billion, a P/E ratio of 28.40, a P/E/G ratio of 6.31 and a beta of 1.05.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.26 by $0.06. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The business had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. During the same quarter last year, the business earned $1.43 earnings per share. Agilent Technologies’s quarterly revenue was down 5.6% compared to the same quarter last year. As a group, equities analysts predict that Agilent Technologies, Inc. will post 5.24 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, October 23rd. Shareholders of record on Tuesday, October 1st were paid a dividend of $0.236 per share. The ex-dividend date was Tuesday, October 1st. This represents a $0.94 annualized dividend and a yield of 0.69%. Agilent Technologies’s payout ratio is currently 19.50%.

Insider Buying and Selling at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total value of $283,910.00. Following the completion of the sale, the chief executive officer now directly owns 24,118 shares in the company, valued at $3,497,110. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, SVP Dominique Grau sold 9,990 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the transaction, the senior vice president now owns 40,011 shares of the company’s stock, valued at approximately $5,801,595. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total value of $283,910.00. Following the sale, the chief executive officer now directly owns 24,118 shares of the company’s stock, valued at $3,497,110. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,995 shares of company stock worth $1,739,510 over the last ninety days.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Citigroup raised their price objective on Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Barclays lifted their price target on shares of Agilent Technologies from $135.00 to $145.00 and gave the company an “underweight” rating in a report on Tuesday, October 15th. Evercore ISI increased their price objective on shares of Agilent Technologies from $135.00 to $145.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Stifel Nicolaus restated a “buy” rating and set a $151.00 target price on shares of Agilent Technologies in a research note on Monday, August 26th. Finally, UBS Group increased their price target on Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a research note on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $144.36.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.